1 / 1

A Brief Introduction of Antibody Drug Conjugate

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs (cytotoxic payloads) by chemical linkers with labile bonds.<br>

CreativeBiolabs
Download Presentation

A Brief Introduction of Antibody Drug Conjugate

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANTIBODY-DRUG CONJUGATE Structure of antibody-drug conjugate (ADC) 1 Antibody-Drug Conjugates (ADCs) are antibodies (mAbs) attached to biologically active drugs (cytotoxic payloads) chemical linkers with labile bonds. monoclonal Monoclonal antibody ·Antibody properties ·Internalization ·Receptor-mediated endocytosis by Cytotoxic payload ·Microtuble inhibitors -Auristatins -Maytansines ·DNA synthesis inhibitors -Calicheamicm -Doxorubicin -Duocarmycine -Pyrrolobenzodiazepine ·Topoisomerase inhibitors -Quinoline alkaloids Linker Antibodies proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer cell. By combin- ing the targeting capabili- ties of monoclonal antibod- ies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow for discrimination between healthy diseased tissue. track these ·Cleavable -Acid-labile -Protease cleavable -Disulphide linkage ·Non-cleavable -Thioether -Maleimidocaproyl Mechanism of action of ADC 2 Route 2 Inhibite microtubles ADC Binding Microtubules Route 3 Inhibite topoisomerase Route 3 Route 2 Route 1 Inhibite DNA synthesis Route 1 Nucleus Tumor cell and Internalization Release Degradation To date, four ADCs have received market approval. Gemtuzumab ozogamicin for treatment of acute myelogenous Brentuximab vedotin for treatment of relapsed or refractory Hodgkin lym- phoma (HL) and systemic anaplastic lymphoma (ALCL), Trastu- zumab emtansine tratment of human epider- mal growth factor receptor 2 (HER2)-positive metastat- ic breast cancer (mBC), and Inotuzumab ozogamicin for treatment of relapsed or refractory CD22-positive B-cell precursor lymphoblastic (ALL). Lysosome Endosome leukemia, Approved ADC Products for marketing 3 large cell Name Trade name Company Therapeutic area First approval date for Gemtuzumab ozogamicin Wyeth Pharms Inc. May 11, 2000 (withdraw 2010) Acute myelogenous leukemia Mylotarg Seattle Genetics Relapsed or refractory HL and systemic ALCL Brentuximab vedotin August 19, 2011 Adcetris Trastuzumab emtansine Inotuzumab ozogamicin HER2-positive mBC Kadcyla Genentech February 22, 2013 acute Relapsed or refractory CD22- positive B-cell precursor ALL Wyeth Pharms Inc. leukemia Besponsa August 17, 2017 WHATWEDO: Integrated Solutions for ADC Development Provided by Creative Biolabs Services ADC Antibody Screening Antibody-based Probes DrugLnk™ Custom Synthesis Antibody Design and Conjugation ADC in vivo/in vitro Analysis & Manufacturing Products Customized ADCs DrugLnk products Anti-Ab ADCs Anti-drug Abs © 2007 - 2018 Creative-Biolabs All Rights Reserved Email: info@creative-biolabs.com Tel: 1-631-381-2994

More Related